Our client, Biotech company Immunai inc., closed a major investment from Koch Disruptive Technologies as lead investor and other new and existing investors.
Immunai works to map the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes. The investment of about $215M will allow the company to continue breaking new grounds in this innovative and important field.
Our partners Yair Geva and Yuval Zilber, with their team, associate Reggev Mechalovich and intern Jael Tahan, worked on this deal.

For further reading >> click here